Anish Suri - Sep 23, 2021 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role: PRESIDENT AND CSO
Signature: /s/ Anish Suri by Colin Sandercock, attorney-in-fact
Stock symbol: CUE
Transactions as of: Sep 23, 2021
Transactions value $: -$176,246
Form type: 4
Date filed: 9/27/2021, 04:30 PM
Next filing: Oct 8, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CUE	Common Stock	Options Exercise	$128K	+20K	+26.72%	$6.42	94.8K	Sep 23, 2021	Direct	F1
transaction	CUE	Common Stock	Sale	-$305K	-20K	-21.09%	$15.23	74.8K	Sep 23, 2021	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CUE	Stock Option (right to buy)	Options Exercise	$0	-20K	-13.79%	$0.00	125K	Sep 23, 2021	Common Stock	20K	$6.42	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 24, 2020.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.58, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4.
F3	The option vests in eight equal semi-annual installments beginning September 6, 2019.